Eric Venker Sells 177,704 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 177,704 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the completion of the sale, the chief operating officer now owns 740,976 shares of the company’s stock, valued at $8,550,863.04. This represents a 19.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $11.83 on Thursday. The stock has a 50 day moving average price of $11.91 and a 200 day moving average price of $11.55. Roivant Sciences Ltd. has a 52 week low of $9.69 and a 52 week high of $13.06. The stock has a market capitalization of $8.61 billion, a PE ratio of 2.09 and a beta of 1.25.

Institutional Trading of Roivant Sciences

Hedge funds have recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $34,000. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences in the third quarter valued at approximately $35,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $36,000. US Bancorp DE lifted its position in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Roivant Sciences in the second quarter valued at approximately $53,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Bank of America increased their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.